Covid-19 vaccine development and deployment – how can we manage expectations and ensure responsible, balanced decision making?
We would like to work with an agency, or partnership of agencies, to develop a pipeline of content that explores the intricacies of Covid-19 vaccine development. The aim is to promote balanced conversations on the topic and ensure responsible, informed decision making.
The chosen partner will also be asked to develop a marketing strategy for the content.
The deadline for expressions of interest is 2 October 2020, 17:00 BST. We'll ask you to submit a full proposal by 14 October 2020, 15.00 BST.
Through this key area of work, we want to:
We’re working across several areas to achieve our goals.
Vaccines are a vital tool for fighting epidemics, but developing a vaccine from scratch typically takes more than 10 years. We’re working to support the development of vaccines against known diseases, and of new technology to accelerate vaccine development when new threats appear.
Vaccines work best when they are developed specifically for the populations most at risk. An effective way to do this is through human infection studies, which involve testing the vaccines on volunteers from relevant communities.
Vaccines can help prevent infections which are resistant to antibiotics, and diseases which can lead to unnecessary prescription of antibiotics. But they’re not used enough as a tool to tackle drug-resistant infections.
For this, we:
For advances in vaccine science to benefit more people, more quickly, implementation and evidence need to be more closely linked.
One example where this link could be stronger is between cholera control and research. Cholera, often thought of as a disease of history, still causes an estimated 2.9 million cases and 95,000 deaths every year.
Countries, particularly low- and middle-income countries with high burdens of infectious disease, need to be able to develop independent policies on immunisation that are based on research evidence, local disease burden and cost-effectiveness. To do this, they need access to relevant evidence, clear decision-making pathways, and technical skills and expertise.
We’re working to identify, fund, share and apply relevant research so that decisions can be based on better information. This includes:
Vaccines already save millions of lives, but they could be saving many millions more. This can only happen with the support of global policy makers.
The world is waiting eagerly for Covid-19 vaccines to be developed as quickly as possible. But to make sure they are safe and effective, the clinical trials that test them have to be robust. So how do trials achieve this?
A COVID-19 vaccine would be an incredibly powerful tool to slow down the coronavirus pandemic. How do we develop one in record time?
Vaccines are one of our most effective health interventions, but are often misunderstood. In this Q&A, we explain what they are, how they work and why they are important.